Efficacy of monoterpene perillyl alcohol upon survival rate of patients with recurrent glioblastoma
Purpose The monoterpene perillyl alcohol (POH) a Ras inhibitor with potential capacity to arrest gliomagenesis is being used in a phase I/II clinical trial in adults with recurrent malignant glioma. The present study aimed to investigate the efficacy of intranasal administration of monoterpene POH u...
Gespeichert in:
| Veröffentlicht in: | Journal of cancer research and clinical oncology 2011-02, Vol.137 (2), p.287-293 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 293 |
|---|---|
| container_issue | 2 |
| container_start_page | 287 |
| container_title | Journal of cancer research and clinical oncology |
| container_volume | 137 |
| creator | da Fonseca, Clovis O Simão, Marcela Lins, Igor R Caetano, Regina O Futuro, Débora Quirico-Santos, Thereza |
| description | Purpose The monoterpene perillyl alcohol (POH) a Ras inhibitor with potential capacity to arrest gliomagenesis is being used in a phase I/II clinical trial in adults with recurrent malignant glioma. The present study aimed to investigate the efficacy of intranasal administration of monoterpene POH upon survival rate of patients with recurrent glioblastoma (GBM) in comparison with historical control group of GBM patients. Patients and methods It was included 89 adults with recurrent GBM receiving daily intranasal administration of 440 mg POH and 52 matched GBM patients as historical control untreated group only with supportive treatment. Results Patients with recurrent primary GBM treated with POH survived significantly longer (log rank test, P < 0.0001) than untreated group. Patients with recurrent primary GBM in deep location survived significantly longer than with lobar location (log rank test, P < 0.0001). Median survival rate of secondary GBM was 11.2 months, longer (log rank test, P = 0.0366) than primary GBM (5.9 months). Radiographic improvement and reduction of corticosteroid dosage (36%) further associated with a delay towards progression. Conclusion Intranasal administration of POH increased the overall survival of patients with recurrent GBM in comparison with historical untreated controls, but especially patients with secondary GBM and primary GBM with tumor localized in deep regions of the brain. The side effects of POH treatment were almost nonexistent, even in patients treated for over 4 years. |
| doi_str_mv | 10.1007/s00432-010-0873-0 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_904469779</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>904469779</sourcerecordid><originalsourceid>FETCH-LOGICAL-c456t-d69efa4299d55f894e8a0cac185ca64b2495e8c43a43b62b522782a961e9db73</originalsourceid><addsrcrecordid>eNqFkUtv1TAQhS0EopfCD2ADFhJiFRi_7WVVlYdUiQVlbTm-zm0qJw52UnT_PY5yoRILWFljf-fMjA9CLwm8JwDqQwHgjDZAoAGtWAOP0I6sN4Qx8RjtgCjSCErkGXpWyh3UWij6FJ1R4ECkgh3yV13Xe-ePOHV4SGOaQ57CGPAUch_jMWIXfbpNES9TGnFZ8n1_7yLObg6rZHJzH8a54J_9fItz8EvOtcaH2Kc2ujKnwT1HTzoXS3hxOs_Rzcerm8vPzfXXT18uL64bz4Wcm700oXOcGrMXotOGB-2gjka08E7ylnIjgvacOc5aSVtBqdLUGUmC2beKnaN3m-2U048llNkOffEhRjeGtBRrgHNplDL_JbUQFLShK_nmL_IuLXmsW1jNiADBlKwQ2SCfUyk5dHbK_eDy0RKwa1B2C8rWoOwalIWqeXUyXtoh7P8ofidTgbcnwBXvYpfd6PvywDFdfwrWrenGlfo0HkJ-mPBf3V9vos4l6w65Gn__RoEwIIZKTTn7BcXftCg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>831505376</pqid></control><display><type>article</type><title>Efficacy of monoterpene perillyl alcohol upon survival rate of patients with recurrent glioblastoma</title><source>MEDLINE</source><source>Springer Online Journals</source><creator>da Fonseca, Clovis O ; Simão, Marcela ; Lins, Igor R ; Caetano, Regina O ; Futuro, Débora ; Quirico-Santos, Thereza</creator><creatorcontrib>da Fonseca, Clovis O ; Simão, Marcela ; Lins, Igor R ; Caetano, Regina O ; Futuro, Débora ; Quirico-Santos, Thereza</creatorcontrib><description>Purpose The monoterpene perillyl alcohol (POH) a Ras inhibitor with potential capacity to arrest gliomagenesis is being used in a phase I/II clinical trial in adults with recurrent malignant glioma. The present study aimed to investigate the efficacy of intranasal administration of monoterpene POH upon survival rate of patients with recurrent glioblastoma (GBM) in comparison with historical control group of GBM patients. Patients and methods It was included 89 adults with recurrent GBM receiving daily intranasal administration of 440 mg POH and 52 matched GBM patients as historical control untreated group only with supportive treatment. Results Patients with recurrent primary GBM treated with POH survived significantly longer (log rank test, P < 0.0001) than untreated group. Patients with recurrent primary GBM in deep location survived significantly longer than with lobar location (log rank test, P < 0.0001). Median survival rate of secondary GBM was 11.2 months, longer (log rank test, P = 0.0366) than primary GBM (5.9 months). Radiographic improvement and reduction of corticosteroid dosage (36%) further associated with a delay towards progression. Conclusion Intranasal administration of POH increased the overall survival of patients with recurrent GBM in comparison with historical untreated controls, but especially patients with secondary GBM and primary GBM with tumor localized in deep regions of the brain. The side effects of POH treatment were almost nonexistent, even in patients treated for over 4 years.</description><identifier>ISSN: 0171-5216</identifier><identifier>EISSN: 1432-1335</identifier><identifier>DOI: 10.1007/s00432-010-0873-0</identifier><identifier>PMID: 20401670</identifier><identifier>CODEN: JCROD7</identifier><language>eng</language><publisher>Berlin/Heidelberg: Berlin/Heidelberg : Springer-Verlag</publisher><subject>Administration, Intranasal ; Adult ; Aged ; Aged, 80 and over ; Antineoplastic agents ; Antineoplastic Agents - administration & dosage ; Antineoplastic Agents - therapeutic use ; Biological and medical sciences ; Brain cancer ; Brain Neoplasms - drug therapy ; Brain Neoplasms - mortality ; Brain Neoplasms - pathology ; Cancer Research ; Cellular biology ; Clinical outcomes ; Drug Administration Schedule ; Drug delivery systems ; Female ; Glioblastoma ; Glioblastoma - drug therapy ; Glioblastoma - mortality ; Glioblastoma - pathology ; Hematology ; Humans ; Internal Medicine ; intranasal administration ; Kaplan-Meier Estimate ; Magnetic Resonance Imaging ; Male ; Medical sciences ; Medicine ; Medicine & Public Health ; Middle Aged ; Monoterpenes - administration & dosage ; Monoterpenes - therapeutic use ; Neoplasm Recurrence, Local - drug therapy ; Neoplasm Recurrence, Local - mortality ; Neoplasm Recurrence, Local - pathology ; Neurology ; Oncology ; Original Paper ; Patient Selection ; Perillyl alcohol ; Pharmacology. Drug treatments ; Phytochemicals ; Survival analysis ; Terpene ; Tumor topography ; Tumors of the nervous system. Phacomatoses</subject><ispartof>Journal of cancer research and clinical oncology, 2011-02, Vol.137 (2), p.287-293</ispartof><rights>Springer-Verlag 2010</rights><rights>2015 INIST-CNRS</rights><rights>Springer-Verlag 2011</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c456t-d69efa4299d55f894e8a0cac185ca64b2495e8c43a43b62b522782a961e9db73</citedby><cites>FETCH-LOGICAL-c456t-d69efa4299d55f894e8a0cac185ca64b2495e8c43a43b62b522782a961e9db73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00432-010-0873-0$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00432-010-0873-0$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,777,781,27905,27906,41469,42538,51300</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23842907$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20401670$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>da Fonseca, Clovis O</creatorcontrib><creatorcontrib>Simão, Marcela</creatorcontrib><creatorcontrib>Lins, Igor R</creatorcontrib><creatorcontrib>Caetano, Regina O</creatorcontrib><creatorcontrib>Futuro, Débora</creatorcontrib><creatorcontrib>Quirico-Santos, Thereza</creatorcontrib><title>Efficacy of monoterpene perillyl alcohol upon survival rate of patients with recurrent glioblastoma</title><title>Journal of cancer research and clinical oncology</title><addtitle>J Cancer Res Clin Oncol</addtitle><addtitle>J Cancer Res Clin Oncol</addtitle><description>Purpose The monoterpene perillyl alcohol (POH) a Ras inhibitor with potential capacity to arrest gliomagenesis is being used in a phase I/II clinical trial in adults with recurrent malignant glioma. The present study aimed to investigate the efficacy of intranasal administration of monoterpene POH upon survival rate of patients with recurrent glioblastoma (GBM) in comparison with historical control group of GBM patients. Patients and methods It was included 89 adults with recurrent GBM receiving daily intranasal administration of 440 mg POH and 52 matched GBM patients as historical control untreated group only with supportive treatment. Results Patients with recurrent primary GBM treated with POH survived significantly longer (log rank test, P < 0.0001) than untreated group. Patients with recurrent primary GBM in deep location survived significantly longer than with lobar location (log rank test, P < 0.0001). Median survival rate of secondary GBM was 11.2 months, longer (log rank test, P = 0.0366) than primary GBM (5.9 months). Radiographic improvement and reduction of corticosteroid dosage (36%) further associated with a delay towards progression. Conclusion Intranasal administration of POH increased the overall survival of patients with recurrent GBM in comparison with historical untreated controls, but especially patients with secondary GBM and primary GBM with tumor localized in deep regions of the brain. The side effects of POH treatment were almost nonexistent, even in patients treated for over 4 years.</description><subject>Administration, Intranasal</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Agents - administration & dosage</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Brain cancer</subject><subject>Brain Neoplasms - drug therapy</subject><subject>Brain Neoplasms - mortality</subject><subject>Brain Neoplasms - pathology</subject><subject>Cancer Research</subject><subject>Cellular biology</subject><subject>Clinical outcomes</subject><subject>Drug Administration Schedule</subject><subject>Drug delivery systems</subject><subject>Female</subject><subject>Glioblastoma</subject><subject>Glioblastoma - drug therapy</subject><subject>Glioblastoma - mortality</subject><subject>Glioblastoma - pathology</subject><subject>Hematology</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>intranasal administration</subject><subject>Kaplan-Meier Estimate</subject><subject>Magnetic Resonance Imaging</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Monoterpenes - administration & dosage</subject><subject>Monoterpenes - therapeutic use</subject><subject>Neoplasm Recurrence, Local - drug therapy</subject><subject>Neoplasm Recurrence, Local - mortality</subject><subject>Neoplasm Recurrence, Local - pathology</subject><subject>Neurology</subject><subject>Oncology</subject><subject>Original Paper</subject><subject>Patient Selection</subject><subject>Perillyl alcohol</subject><subject>Pharmacology. Drug treatments</subject><subject>Phytochemicals</subject><subject>Survival analysis</subject><subject>Terpene</subject><subject>Tumor topography</subject><subject>Tumors of the nervous system. Phacomatoses</subject><issn>0171-5216</issn><issn>1432-1335</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkUtv1TAQhS0EopfCD2ADFhJiFRi_7WVVlYdUiQVlbTm-zm0qJw52UnT_PY5yoRILWFljf-fMjA9CLwm8JwDqQwHgjDZAoAGtWAOP0I6sN4Qx8RjtgCjSCErkGXpWyh3UWij6FJ1R4ECkgh3yV13Xe-ePOHV4SGOaQ57CGPAUch_jMWIXfbpNES9TGnFZ8n1_7yLObg6rZHJzH8a54J_9fItz8EvOtcaH2Kc2ujKnwT1HTzoXS3hxOs_Rzcerm8vPzfXXT18uL64bz4Wcm700oXOcGrMXotOGB-2gjka08E7ylnIjgvacOc5aSVtBqdLUGUmC2beKnaN3m-2U048llNkOffEhRjeGtBRrgHNplDL_JbUQFLShK_nmL_IuLXmsW1jNiADBlKwQ2SCfUyk5dHbK_eDy0RKwa1B2C8rWoOwalIWqeXUyXtoh7P8ofidTgbcnwBXvYpfd6PvywDFdfwrWrenGlfo0HkJ-mPBf3V9vos4l6w65Gn__RoEwIIZKTTn7BcXftCg</recordid><startdate>20110201</startdate><enddate>20110201</enddate><creator>da Fonseca, Clovis O</creator><creator>Simão, Marcela</creator><creator>Lins, Igor R</creator><creator>Caetano, Regina O</creator><creator>Futuro, Débora</creator><creator>Quirico-Santos, Thereza</creator><general>Berlin/Heidelberg : Springer-Verlag</general><general>Springer-Verlag</general><general>Springer</general><general>Springer Nature B.V</general><scope>FBQ</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>7TK</scope></search><sort><creationdate>20110201</creationdate><title>Efficacy of monoterpene perillyl alcohol upon survival rate of patients with recurrent glioblastoma</title><author>da Fonseca, Clovis O ; Simão, Marcela ; Lins, Igor R ; Caetano, Regina O ; Futuro, Débora ; Quirico-Santos, Thereza</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c456t-d69efa4299d55f894e8a0cac185ca64b2495e8c43a43b62b522782a961e9db73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Administration, Intranasal</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Agents - administration & dosage</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Brain cancer</topic><topic>Brain Neoplasms - drug therapy</topic><topic>Brain Neoplasms - mortality</topic><topic>Brain Neoplasms - pathology</topic><topic>Cancer Research</topic><topic>Cellular biology</topic><topic>Clinical outcomes</topic><topic>Drug Administration Schedule</topic><topic>Drug delivery systems</topic><topic>Female</topic><topic>Glioblastoma</topic><topic>Glioblastoma - drug therapy</topic><topic>Glioblastoma - mortality</topic><topic>Glioblastoma - pathology</topic><topic>Hematology</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>intranasal administration</topic><topic>Kaplan-Meier Estimate</topic><topic>Magnetic Resonance Imaging</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Monoterpenes - administration & dosage</topic><topic>Monoterpenes - therapeutic use</topic><topic>Neoplasm Recurrence, Local - drug therapy</topic><topic>Neoplasm Recurrence, Local - mortality</topic><topic>Neoplasm Recurrence, Local - pathology</topic><topic>Neurology</topic><topic>Oncology</topic><topic>Original Paper</topic><topic>Patient Selection</topic><topic>Perillyl alcohol</topic><topic>Pharmacology. Drug treatments</topic><topic>Phytochemicals</topic><topic>Survival analysis</topic><topic>Terpene</topic><topic>Tumor topography</topic><topic>Tumors of the nervous system. Phacomatoses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>da Fonseca, Clovis O</creatorcontrib><creatorcontrib>Simão, Marcela</creatorcontrib><creatorcontrib>Lins, Igor R</creatorcontrib><creatorcontrib>Caetano, Regina O</creatorcontrib><creatorcontrib>Futuro, Débora</creatorcontrib><creatorcontrib>Quirico-Santos, Thereza</creatorcontrib><collection>AGRIS</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest research library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>Neurosciences Abstracts</collection><jtitle>Journal of cancer research and clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>da Fonseca, Clovis O</au><au>Simão, Marcela</au><au>Lins, Igor R</au><au>Caetano, Regina O</au><au>Futuro, Débora</au><au>Quirico-Santos, Thereza</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy of monoterpene perillyl alcohol upon survival rate of patients with recurrent glioblastoma</atitle><jtitle>Journal of cancer research and clinical oncology</jtitle><stitle>J Cancer Res Clin Oncol</stitle><addtitle>J Cancer Res Clin Oncol</addtitle><date>2011-02-01</date><risdate>2011</risdate><volume>137</volume><issue>2</issue><spage>287</spage><epage>293</epage><pages>287-293</pages><issn>0171-5216</issn><eissn>1432-1335</eissn><coden>JCROD7</coden><abstract>Purpose The monoterpene perillyl alcohol (POH) a Ras inhibitor with potential capacity to arrest gliomagenesis is being used in a phase I/II clinical trial in adults with recurrent malignant glioma. The present study aimed to investigate the efficacy of intranasal administration of monoterpene POH upon survival rate of patients with recurrent glioblastoma (GBM) in comparison with historical control group of GBM patients. Patients and methods It was included 89 adults with recurrent GBM receiving daily intranasal administration of 440 mg POH and 52 matched GBM patients as historical control untreated group only with supportive treatment. Results Patients with recurrent primary GBM treated with POH survived significantly longer (log rank test, P < 0.0001) than untreated group. Patients with recurrent primary GBM in deep location survived significantly longer than with lobar location (log rank test, P < 0.0001). Median survival rate of secondary GBM was 11.2 months, longer (log rank test, P = 0.0366) than primary GBM (5.9 months). Radiographic improvement and reduction of corticosteroid dosage (36%) further associated with a delay towards progression. Conclusion Intranasal administration of POH increased the overall survival of patients with recurrent GBM in comparison with historical untreated controls, but especially patients with secondary GBM and primary GBM with tumor localized in deep regions of the brain. The side effects of POH treatment were almost nonexistent, even in patients treated for over 4 years.</abstract><cop>Berlin/Heidelberg</cop><pub>Berlin/Heidelberg : Springer-Verlag</pub><pmid>20401670</pmid><doi>10.1007/s00432-010-0873-0</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0171-5216 |
| ispartof | Journal of cancer research and clinical oncology, 2011-02, Vol.137 (2), p.287-293 |
| issn | 0171-5216 1432-1335 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_904469779 |
| source | MEDLINE; Springer Online Journals |
| subjects | Administration, Intranasal Adult Aged Aged, 80 and over Antineoplastic agents Antineoplastic Agents - administration & dosage Antineoplastic Agents - therapeutic use Biological and medical sciences Brain cancer Brain Neoplasms - drug therapy Brain Neoplasms - mortality Brain Neoplasms - pathology Cancer Research Cellular biology Clinical outcomes Drug Administration Schedule Drug delivery systems Female Glioblastoma Glioblastoma - drug therapy Glioblastoma - mortality Glioblastoma - pathology Hematology Humans Internal Medicine intranasal administration Kaplan-Meier Estimate Magnetic Resonance Imaging Male Medical sciences Medicine Medicine & Public Health Middle Aged Monoterpenes - administration & dosage Monoterpenes - therapeutic use Neoplasm Recurrence, Local - drug therapy Neoplasm Recurrence, Local - mortality Neoplasm Recurrence, Local - pathology Neurology Oncology Original Paper Patient Selection Perillyl alcohol Pharmacology. Drug treatments Phytochemicals Survival analysis Terpene Tumor topography Tumors of the nervous system. Phacomatoses |
| title | Efficacy of monoterpene perillyl alcohol upon survival rate of patients with recurrent glioblastoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T17%3A17%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20of%20monoterpene%20perillyl%20alcohol%20upon%20survival%20rate%20of%20patients%20with%20recurrent%20glioblastoma&rft.jtitle=Journal%20of%20cancer%20research%20and%20clinical%20oncology&rft.au=da%20Fonseca,%20Clovis%20O&rft.date=2011-02-01&rft.volume=137&rft.issue=2&rft.spage=287&rft.epage=293&rft.pages=287-293&rft.issn=0171-5216&rft.eissn=1432-1335&rft.coden=JCROD7&rft_id=info:doi/10.1007/s00432-010-0873-0&rft_dat=%3Cproquest_cross%3E904469779%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=831505376&rft_id=info:pmid/20401670&rfr_iscdi=true |